On October 23, 2025 Verismo Therapeutics, a clinical-stage CAR T company developing a novel KIR-CAR platform technology, reported its participation and sponsorship of the International Mesothelioma Interest Group (iMig) 2025 Conference. The company will highlight STAR-101, an ongoing Phase 1 clinical trial of Verismo’s lead pipeline SynKIR-110 in patients with advanced mesothelin-expressing cancers, including mesothelioma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mesothelioma is a rare, aggressive cancer, with more than 2,500 people diagnosed annually in the United States and 30,000 globally1. Despite recent therapeutic advances, prognosis remains poor and most patients face limited options for long-term treatment. SynKIR-110 targets mesothelin, a protein highly expressed on mesothelioma cells and a validated target for innovative immunotherapies, enabling it to recognize and attack the cancer cells. SynKIR-110 was granted Orphan Drug and Fast Track Designations by the Food and Drug Administration for treatment of mesothelioma in 2022 and 2023, respectively.
"Mesothelioma is one of the most difficult cancers to treat, and it has historically been underserved in terms of new treatment development," said Daniel Sterman, M.D., Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine at the NYU Grossman School of Medicine, Director of Division of Pulmonary Medicine at the NYU Langone Medical Center and an organizer of iMig 2025. "By sponsoring iMig and presenting the STAR-101 trial design, Verismo is demonstrating its commitment to advancing the science, addressing the unmet medical need, and supporting the global mesothelioma community." Dr. Sterman serves as the Medical Monitor for Verismo’s STAR-101 clinical study.
STAR-101 (NCT05568680) is a multicenter, open-label, Phase 1 study designed to evaluate the safety, feasibility, and preliminary efficacy of SynKIR-110 in patients with advanced mesothelin-expressing tumors. The trial is the first to bring Verismo’s multi-chain KIR-CAR platform into the clinic for solid tumors.
Verismo’s sponsorship of iMig 2025 underscores its dedication not only to scientific innovation but also to supporting patients, clinicians, and advocates working to advance care in mesothelioma worldwide.
Presentation Details:
Title: SynKIR-CAR T Cell Advanced Research (STAR)-101 Phase 1 Clinical Trial for Patients with Advanced Mesothelin-expressing Mesothelioma, Ovarian Cancer, or Cholangiocarcinoma
Session: Novel Combinations and Applications of Immunotherapy; Salon E
Date/Time: Monday, October 27, 2025, 2:30 – 2:45 PM
Presenter: Jun Xu, Ph.D., Executive Director of Translational Science, Verismo Therapeutics
(Press release, Verismo Therapeutics, OCT 23, 2025, View Source [SID1234656965])